Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Tenofovir alafenamide

Catalog No: tcsc3366

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
379270-37-8

Formula:
$C_{21}H_{29}N_6O_5P$

Pathway:
Anti-infection;Anti-infection

Target:
Reverse Transcriptase;HIV

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 31 mg/mL (65.06 mM); H2O : 6.67 mg/mL (14.00 mM; Need ultrasonic)

Alternative Names:
GS-7340

Observed Molecular Weight:
476.47

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.

IC50 & Target: HIV-1, NRTIs[1]

In Vitro: Tenofovir alafenamide antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC_{50} varies from 4.7 to 42 μM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC_{50}s range from 0.1 to 12 nM, with a mean EC_{50} of 3.5 nM compared to a mean EC_{50} of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC_{50}s are 1.8 nM for TAF and 6.4 nM for AZT[2].

In Vivo: Tenofovir alafenamide hemifumarate is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF)[1].